| Brittany Bogan, DOCTOR OF PHARMACY | |
|
39 Hinesburg Rd, South Burlington, VT 05403-6526 | |
| (802) 882-5722 | |
| Not Available |
| Full Name | Brittany Bogan |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 39 Hinesburg Rd, South Burlington, Vermont |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1588117329 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 033.0119964 (Vermont) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Brittany Bogan, DOCTOR OF PHARMACY 13 1/2 Pond St, Newburyport, MA 01950-3900 Ph: (978) 462-5339 | Brittany Bogan, DOCTOR OF PHARMACY 39 Hinesburg Rd, South Burlington, VT 05403-6526 Ph: (802) 882-5722 |
News Archive
As part of a national clinical trial, UT Southwestern Medical Center researchers found little difference in effectiveness between two popular treatments for one of the most common ailments among American women: stress urinary incontinence.
The U.S. Food and Drug Administration today approved the first genetic test that can help some colorectal cancer (CRC) patients and their doctors determine if the drug Erbitux (cetuximab) would be an effective treatment based on the absence of a gene mutation. The therascreen KRAS RGQ PCR Kit can provide information about the KRAS gene mutation in patients whose CRC has spread to other parts of their body (metastasized).
With the threat of a shortage of protective masks looming as the novel coronavirus pandemic grows, Medical University of South Carolina biomedical engineers and tinkerers had an inspired idea: unleash an army of makers from across the U.S. who could make such masks from 3D printers - a technology that, in recent years, has become widely available.
Researchers at The University of Texas M. D. Anderson Cancer Center are testing a new technique for identifying circulating genetically abnormal cells, which can lead to poor prognosis, in patients with non-small cell lung cancer.
Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it has submitted a Pediatric Investigation Plan (PIP) to the European Medicines Agency (EMEA) as part of the required filing process for approval of pixantrone for treating relapsed or refractory, aggressive non-Hodgkin's Lymphoma (NHL) in Europe. The PIP outlines how the company proposes to study the drug in children in order to benefit child health.
› Verified 9 days ago
Ling Ling Huang, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1653 Williston Rd, South Burlington, VT 05403 Phone: 802-860-0714 | |
Ashley Lacey, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 39 Hinesburg Rd, South Burlington, VT 05403 Phone: 802-862-5722 | |
Steven A Hollister, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 935 Shelburne Rd, South Burlington, VT 05403 Phone: 802-863-1842 | |
Sarah J Stephens, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1653 Williston Rd, South Burlington, VT 05403 Phone: 802-860-0714 Fax: 802-860-1407 | |
Mckenzie L Stannard, PHARM.D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1 Dorset St, South Burlington, VT 05403 Phone: 802-651-1449 | |
Dr. Meghan Barry Bissonnette, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1 Dorset St, South Burlington, VT 05403 Phone: 802-651-1449 | |
Thomas French, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1653 Williston Rd, South Burlington, VT 05403 Phone: 802-860-0714 Fax: 802-860-1407 |